Clinical Trial Update: Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update evaluating alpha-lipoic acid to prevent cisplatin-induced hearing loss in cancer patients; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hearing Loss

Drugs mentioned

• Alpha Lipoic Acid (alpha-lipoic acid)
• CISPLATIN (cisplatin)

Snippet

Sponsor: US Department of Veterans Affairs | Conditions: Ototoxicity, Unspecified Adult Solid Tumor | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-01-29